Analysis Of Income And Expense [Abstract]

OSE Immunotherapeutics - Filing #2816794

Concept	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2020-01-01 to 2020-12-31	2020-01-01 to 2020-12-31	2020-01-01 to 2020-12-31	2020-01-01 to 2020-12-31	2020-01-01 to 2020-12-31	2020-01-01 to 2020-12-31
Analysis of income and expense [abstract]
Revenue [abstract]
Other revenue	—	—	—	—	—	0 EUR	—	13,000 EUR	—	—	—	—
Revenue	—	—	—	—	—	26 306 EUR	—	10 432 EUR	—	—	—	—
Material income and expense [abstract]
Research and development expense	—	—	—	—	—	30 550 EUR	—	22 355 EUR	—	—	—	—
Other operating income (expense)	—	—	—	—	—	0 EUR	—	0 EUR	—	—	—	—
Selling, general and administrative expense [abstract]
General and administrative expense	—	—	—	—	—	8 608 EUR	—	4 783 EUR	—	—	—	—
Expenses by nature [abstract]
Classes of employee benefits expense [abstract]
Expense from share-based payment transactions with employees	—	—	—	—	—	3 773 EUR	—	2 283 EUR	—	—	—	—
Miscellaneous other comprehensive income [abstract]
Other comprehensive income, net of tax, exchange differences on translation of foreign operations and hedges of net investments in foreign operations [abstract]
Other comprehensive income, net of tax, exchange differences on translation of foreign operations	—	—	—	—	55,000 EUR	55,000 EUR	—	4,000 EUR	4,000 EUR	—	—	—
Comprehensive income, continuing and discontinued operations [abstract]
Comprehensive income	16 825 EUR	0 EUR	0 EUR	0 EUR	55,000 EUR	16 879 EUR	0 EUR	16 561 EUR	4,000 EUR	0 EUR	0 EUR	16 558 EUR